XML 54 R41.htm IDEA: XBRL DOCUMENT
v3.23.3

Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details) - USD ($) $ in Thousands |  | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Sep. 11, 2023 | Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022
Asset Acquisition [Line Items] |  |  |  |  |
Research and development |  | $ 332,585 | $ 198,837 | $ 799,401 | $ 554,989
Research Collaborations, In-Licensing Arrangements and Other Business Development Activities |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |
Research and development |  | 103,500 |  | 165,000 |
Collaborative arrangement, maximum aggregate development milestone payments |  | 774,000 |  | 774,000 |
Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments |  | 3,900,000 |  | 3,900,000 |
Collaborative arrangement, maximum aggregate regulatory milestone payments |  | 615,200 |  | 615,200 |
Insilico Medicine |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |
Collaborative arrangement, upfront payment | $ 80,000 |  |  |  |
Collaborative arrangement, maximum aggregate development milestone payments |  | 100,000 |  | 100,000 |
Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments |  | $ 775,000 |  | $ 775,000 |

X
- Definition Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments + References No definition available. + Details
Name: | exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments + References No definition available. + Details
Name: | exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments + References No definition available. + Details
Name: | exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights And Obligations, Upfront Payment + References No definition available. + Details
Name: | exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_InsilicoMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |